Background The mainstays of cutaneous leishmaniasis (CL) treatment, in several world
regions, are pentavalent antimony (Sbv) compounds administered parenterally, despite their …

Leishmania is an infectious protozoan parasite related to African and American
trypanosomes. All Leishmania species that are pathogenic to humans can cause dermal …

It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …

Although there have been significant advances in the treatment of visceral leishmaniasis
(VL) and several novel compounds are currently in pre-clinical and clinical development for …

Background Research is urgently needed to reduce the morbidity and mortality of Lassa
fever (LF), including clinical trials to test new therapies and to verify the efficacy and safety of …

Background Leishmaniasis is increasingly reported among travellers. Leishmania species
vary in sensitivity to available therapies. Fast and reliable molecular techniques have made …

Background On the American continent, cutaneous and mucocutaneous leishmaniasis (CL
and MCL) are diseases associated with infection by several species of Leishmania …

Leishmania aethiopica is the etiological agent of cutaneous leishmaniasis (CL) in Ethiopia
and can cause severe and complicated cases such as diffuse CL (DCL), mucocutaneous …

Background Several controlled and uncontrolled studies addressing azole antifungal drugs
for cutaneous and mucosal leishmaniasis have been published with inconclusive results …

Background Mucosal or mucocutaneous leishmaniasis is the most severe form of
tegumentary leishmaniasis due to its destructive character and potential damage to …